Logo

Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate

Share this

Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate

Shots:

  • Eureka and MSK are eligible to receive up front and ~$1B as development- regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use
  • Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform- under its collaboration with MSK
  • Additionally- targeting GPRC5D may improve the durability of response from current therapies and improves the long-term clinical benefits for patients

  Ref: Businesswire | Image: Eureka Therapeutics

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions